Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data
<strong>Background<br></strong> In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/kg) primaquine to be added as a Plasmodium (P.) falciparum gametocytocide to artemisinin-based combination therapy (ACT) without glucose-6-phosphate dehydrogenase...
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
BioMed Central
2022
|
| _version_ | 1826308971185569792 |
|---|---|
| author | Stepniewska, K Allen, EN Humphreys, GS Poirot, E Craig, E Kennon, K Yilma, D Bousema, T Guerin, PJ White, NJ Price, RN Raman, J Martensson, A Mwaiswelo, RO Bancone, G Bastiaens, GJH Bjorkman, A Brown, JM D’Alessandro, U Dicko, AA El-Sayed, B Elzaki, S-E Eziefula, AC Gonçalves, BP Hamid, MMA Kaneko, A Kariuki, S Khan, W Kwambai, TK Ley, B Ngasala, BE Nosten, F Okebe, J Samuels, AM Smit, MR Stone, WJR Sutanto, I Ter Kuile, F Tine, RC Tiono, AB Drakeley, CJ Gosling, R Stergachis, A Barnes, KI Chen, I |
| author_facet | Stepniewska, K Allen, EN Humphreys, GS Poirot, E Craig, E Kennon, K Yilma, D Bousema, T Guerin, PJ White, NJ Price, RN Raman, J Martensson, A Mwaiswelo, RO Bancone, G Bastiaens, GJH Bjorkman, A Brown, JM D’Alessandro, U Dicko, AA El-Sayed, B Elzaki, S-E Eziefula, AC Gonçalves, BP Hamid, MMA Kaneko, A Kariuki, S Khan, W Kwambai, TK Ley, B Ngasala, BE Nosten, F Okebe, J Samuels, AM Smit, MR Stone, WJR Sutanto, I Ter Kuile, F Tine, RC Tiono, AB Drakeley, CJ Gosling, R Stergachis, A Barnes, KI Chen, I |
| author_sort | Stepniewska, K |
| collection | OXFORD |
| description | <strong>Background<br></strong>
In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/kg) primaquine to be added as a Plasmodium (P.) falciparum gametocytocide to artemisinin-based combination therapy (ACT) without glucose-6-phosphate dehydrogenase (G6PD) testing, to accelerate malaria elimination efforts and avoid the spread of artemisinin resistance. Uptake of this recommendation has been relatively slow primarily due to safety concerns.
<br><strong>
Methods<br></strong>
A systematic review and individual patient data (IPD) meta-analysis of single-dose (SD) primaquine studies for P. falciparum malaria were performed. Absolute and fractional changes in haemoglobin concentration within a week and adverse effects within 28 days of treatment initiation were characterised and compared between primaquine and no primaquine arms using random intercept models.
<br><strong>
Results<br></strong>
Data comprised 20 studies that enrolled 6406 participants, of whom 5129 (80.1%) had received a single target dose of primaquine ranging between 0.0625 and 0.75 mg/kg. There was no effect of primaquine in G6PD-normal participants on haemoglobin concentrations. However, among 194 G6PD-deficient African participants, a 0.25 mg/kg primaquine target dose resulted in an additional 0.53 g/dL (95% CI 0.17–0.89) reduction in haemoglobin concentration by day 7, with a 0.27 (95% CI 0.19–0.34) g/dL haemoglobin drop estimated for every 0.1 mg/kg increase in primaquine dose. Baseline haemoglobin, young age, and hyperparasitaemia were the main determinants of becoming anaemic (Hb < 10 g/dL), with the nadir observed on ACT day 2 or 3, regardless of G6PD status and exposure to primaquine. Time to recovery from anaemia took longer in young children and those with baseline anaemia or hyperparasitaemia. Serious adverse haematological events after primaquine were few (9/3, 113, 0.3%) and transitory. One blood transfusion was reported in the primaquine arms, and there were no primaquine-related deaths. In controlled studies, the proportions with either haematological or any serious adverse event were similar between primaquine and no primaquine arms.
<br><strong>
Conclusions<br></strong>
Our results support the WHO recommendation to use 0.25 mg/kg of primaquine as a P. falciparum gametocytocide, including in G6PD-deficient individuals. Although primaquine is associated with a transient reduction in haemoglobin levels in G6PD-deficient individuals, haemoglobin levels at clinical presentation are the major determinants of anaemia in these patients.
<br><strong>
Trial registration<br></strong>
PROSPERO, CRD42019128185 |
| first_indexed | 2024-03-07T07:27:18Z |
| format | Journal article |
| id | oxford-uuid:5e1093c4-3771-4c31-bf3e-b8648870b5da |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:27:18Z |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:5e1093c4-3771-4c31-bf3e-b8648870b5da2022-11-25T17:40:50ZSafety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient dataJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5e1093c4-3771-4c31-bf3e-b8648870b5daEnglishSymplectic ElementsBioMed Central2022Stepniewska, KAllen, ENHumphreys, GSPoirot, ECraig, EKennon, KYilma, DBousema, TGuerin, PJWhite, NJPrice, RNRaman, JMartensson, AMwaiswelo, ROBancone, GBastiaens, GJHBjorkman, ABrown, JMD’Alessandro, UDicko, AAEl-Sayed, BElzaki, S-EEziefula, ACGonçalves, BPHamid, MMAKaneko, AKariuki, SKhan, WKwambai, TKLey, BNgasala, BENosten, FOkebe, JSamuels, AMSmit, MRStone, WJRSutanto, ITer Kuile, FTine, RCTiono, ABDrakeley, CJGosling, RStergachis, ABarnes, KIChen, I<strong>Background<br></strong> In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/kg) primaquine to be added as a Plasmodium (P.) falciparum gametocytocide to artemisinin-based combination therapy (ACT) without glucose-6-phosphate dehydrogenase (G6PD) testing, to accelerate malaria elimination efforts and avoid the spread of artemisinin resistance. Uptake of this recommendation has been relatively slow primarily due to safety concerns. <br><strong> Methods<br></strong> A systematic review and individual patient data (IPD) meta-analysis of single-dose (SD) primaquine studies for P. falciparum malaria were performed. Absolute and fractional changes in haemoglobin concentration within a week and adverse effects within 28 days of treatment initiation were characterised and compared between primaquine and no primaquine arms using random intercept models. <br><strong> Results<br></strong> Data comprised 20 studies that enrolled 6406 participants, of whom 5129 (80.1%) had received a single target dose of primaquine ranging between 0.0625 and 0.75 mg/kg. There was no effect of primaquine in G6PD-normal participants on haemoglobin concentrations. However, among 194 G6PD-deficient African participants, a 0.25 mg/kg primaquine target dose resulted in an additional 0.53 g/dL (95% CI 0.17–0.89) reduction in haemoglobin concentration by day 7, with a 0.27 (95% CI 0.19–0.34) g/dL haemoglobin drop estimated for every 0.1 mg/kg increase in primaquine dose. Baseline haemoglobin, young age, and hyperparasitaemia were the main determinants of becoming anaemic (Hb < 10 g/dL), with the nadir observed on ACT day 2 or 3, regardless of G6PD status and exposure to primaquine. Time to recovery from anaemia took longer in young children and those with baseline anaemia or hyperparasitaemia. Serious adverse haematological events after primaquine were few (9/3, 113, 0.3%) and transitory. One blood transfusion was reported in the primaquine arms, and there were no primaquine-related deaths. In controlled studies, the proportions with either haematological or any serious adverse event were similar between primaquine and no primaquine arms. <br><strong> Conclusions<br></strong> Our results support the WHO recommendation to use 0.25 mg/kg of primaquine as a P. falciparum gametocytocide, including in G6PD-deficient individuals. Although primaquine is associated with a transient reduction in haemoglobin levels in G6PD-deficient individuals, haemoglobin levels at clinical presentation are the major determinants of anaemia in these patients. <br><strong> Trial registration<br></strong> PROSPERO, CRD42019128185 |
| spellingShingle | Stepniewska, K Allen, EN Humphreys, GS Poirot, E Craig, E Kennon, K Yilma, D Bousema, T Guerin, PJ White, NJ Price, RN Raman, J Martensson, A Mwaiswelo, RO Bancone, G Bastiaens, GJH Bjorkman, A Brown, JM D’Alessandro, U Dicko, AA El-Sayed, B Elzaki, S-E Eziefula, AC Gonçalves, BP Hamid, MMA Kaneko, A Kariuki, S Khan, W Kwambai, TK Ley, B Ngasala, BE Nosten, F Okebe, J Samuels, AM Smit, MR Stone, WJR Sutanto, I Ter Kuile, F Tine, RC Tiono, AB Drakeley, CJ Gosling, R Stergachis, A Barnes, KI Chen, I Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data |
| title | Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data |
| title_full | Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data |
| title_fullStr | Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data |
| title_full_unstemmed | Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data |
| title_short | Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data |
| title_sort | safety of single dose primaquine as a plasmodium falciparum gametocytocide a systematic review and meta analysis of individual patient data |
| work_keys_str_mv | AT stepniewskak safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT allenen safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT humphreysgs safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT poirote safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT craige safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT kennonk safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT yilmad safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT bousemat safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT guerinpj safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT whitenj safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT pricern safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT ramanj safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT martenssona safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT mwaisweloro safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT banconeg safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT bastiaensgjh safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT bjorkmana safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT brownjm safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT dalessandrou safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT dickoaa safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT elsayedb safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT elzakise safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT eziefulaac safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT goncalvesbp safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT hamidmma safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT kanekoa safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT kariukis safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT khanw safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT kwambaitk safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT leyb safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT ngasalabe safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT nostenf safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT okebej safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT samuelsam safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT smitmr safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT stonewjr safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT sutantoi safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT terkuilef safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT tinerc safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT tionoab safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT drakeleycj safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT goslingr safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT stergachisa safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT barneski safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata AT cheni safetyofsingledoseprimaquineasaplasmodiumfalciparumgametocytocideasystematicreviewandmetaanalysisofindividualpatientdata |